Published in final edited form as:

Org Lett. 2009 August 6; 11(15): 3282–3285. doi:10.1021/ol900936t.

A Versatile Route to the Tulearin Class of Macrolactones: Synthesis of a Stereoisomer of Tulearin A

Alexander L. Mandel^a, Véronique Bellosta^a, Dennis P. Curran^b, and Janine Cossy^{a,*}

^aLaboratoire de Chimie Organique, ESPCI ParisTech, CNRS 10 rue Vauquelin, 75231 Paris Cedex 05 France

^bProf. D. P. Curran, Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260 USA

Abstract

stereoisomer of tulearin A

A versatile synthetic approach to the tulearin class of macrolactones has been developed and deployed to make a stereoisomer of tulearin A. The knowledge gained about structure and synthesis will expedite the assignment of the stereostructure of this new anti-cancer agent.

In 2008, Kashman *et al.* reported the isolation of tulearin A (**1**) (Figure 1) from the marine sponge Madagascar *Fascaplysinopsis* sp. collected in the Salary Bay north of Tulear.¹ The structure of **1** was elucidated through interpretation of MS, IR, and various one-dimensional and two-dimensional NMR experiments. However, the relative and absolute stereochemistry of **1** remain unknown. Tulearin A (**1**) exhibits potent anti-proliferative activity against human leukemic cell lines K562 and UT7. Activity against K562 cells was notably better; a 0.5 µg/mL solution of **1** inhibited ~60% of proliferation vs. 35% inhibition against the UT7 cells.¹

Due to its promising biological activity and lack of a three-dimensional structure, we designed a synthetic strategy that was capable of producing any stereoisomer of tulearin A (**1**). These stereoisomers could be used to help assign the stereochemistry and to provide information about the stereostructure/activity relationship. Here we describe the single stereoisomer of tulearin **2**.

Our retrosynthetic plan (Figure 2) was to construct the complete structure through the union of three fragments: stannane **25** (the C20–C26 fragment), an acid of type **I** (the C1–C12 fragment), and vinyl iodide **20** (the C13–C19 fragment) through an esterification, ring-closing metathesis, and Stille coupling.

E-mail: janine.cossy@espci.fr.

Supporting Information Available Experimental procedures and characterization of all new compounds.

Both acid **1** and iodide **20** originate from readily available (*S*)-citronellal (**3**), which already contains the methyl stereochemistry at C5 and C15. The stereocenters at C2 and C3 come from an asymmetric aldol reaction, while the substituents at C8 and C9 are installed through a Sharpless asymmetric dihydroxylation.

The alcohol at C17 is formed through a Noyori reduction. The carbamate is challenging because the alcohols at C8 and C9 have to be orthogonally protected to allow its installation before the final deprotection. We envisioned that all of the fragments could be adjusted by choice of reagents to give any stereoisomer.

The synthesis of the C1–C12 fragment **1** began with known aldehyde **4**² derived from (*S*)-citronellal (Scheme 1). Aldehyde **4** and phenyltetrazolylsulfonyl ester **5** were joined in a Julia-Kociensky reaction³ (KHMDs, THF, –78 °C to –45 °C, 69%) to provide alkene **6** with excellent *E* selectivity. Sharpless asymmetric dihydroxylation⁴ of **6** with AD-mix- α in the presence of methanesulfonamide (*t*-BuOH/H₂O 1:1, 0 °C, 96 h) gave rise to a diol that spontaneously cyclized to form the 5-membered lactone **7** exclusively in 85% yield. Thus, the hydroxy groups at C8–C9 (tulearin A numbering) were differentiated, and C8 group was protected as a *p*-methoxybenzyl ether [PMBOC(=NH)CCl₃, La(OTf)₃, toluene, 12 h, 85%] to give lactone **8**. The *p*-methoxybenzyl (PMB) group was chosen because it can later be removed in the presence of silyl protecting groups installed on the hydroxy groups present at C3 and C9.

To cleave the lactone and introduce the double bond for the eventual ring-closing metathesis (RCM), lactone **8** was reduced (DIBAL-H, CH₂Cl₂, –78 °C, 96% yield) and the resulting hemiacetal was treated with the methylphosphonium ylide (MePPh₃, *n*-BuLi, THF, –78 °C to 60 °C, 2 h, 80%) to give alkene **9**. The liberated hydroxy group at C9 was protected with TBSOTf (2,6-lutidine, CH₂Cl₂, 1 h, 96%), and the primary alcohol was deprotected selectively with Oxone⁵ (MeOH, H₂O, 2 h) to yield alcohol **10** (88%). The free alcohol was then oxidized to aldehyde **11** with Dess-Martin periodinane (CH₂Cl₂, 2 h, 85%). To construct the final two stereogenic centers with the carboxylic acid already in place, the versatile Crimmins chiral auxiliary **A**⁶ was chosen and conditions were used to provide the *syn* product. Reagent **A** was treated with TiCl₄, (–)-sparteine, and *N*-methyl pyrrolidinone (CH₂Cl₂, 0 °C) to give an enolate intermediate that was reacted with aldehyde **11** to afford the aldol product **12** in good yield (84%) and with good diastereoselectivity (dr = 94/6). After protection (TBSOTf, 2,6-lutidine, CH₂Cl₂) and saponification⁷ (LiOH, H₂O₂, THF), compound **13** was transformed into acid **14** in 99% yield (over the two steps). Thus, the C1–C12 fragment **14** was obtained in 21.7% yield from (*S*)-citronellal (**3**) over 14 steps.

Alcohol **20**, representing the C13–C19 fragment of target **2**, was also prepared from (*S*)-citronellal (**3**) (Scheme 2). Treatment of **3** with the propynyl Grignard reagent (THF, –78 °C), followed by a Swern oxidation [(COCl)₂, DMSO, Et₃N, CH₂Cl₂, –78 °C], afforded ketone **15** in 71% yield over the two steps.

Noyori reduction⁸ with (*S,S*)-Noyori catalyst **B** (10 mol % in *i*-PrOH) gave alcohol **16** in moderate yield (48%).⁹ Alcohol **16** was transformed into the alkyne **18**, precursor of **20**, through a facile five-step sequence (Scheme 3). To begin, the hydroxy group in **16** was protected (TIPSCl, imidazole, DMF), then the double bond was oxidatively cleaved with ozone followed by *in situ* reduction with NaBH₄ (CH₂Cl₂/MeOH (3:2), –78 °C to rt) to give alcohol **17** in 85% yield (two steps). A three-step sequence¹⁰ involving mesylation (MsCl, Et₃N, CH₂Cl₂), iodination (NaI, THF), and elimination (*t*-BuOK, THF) produced alkyne **18** in good yield (91%). Finally, the alkyne was converted to the desired vinyl iodide **19** through the (*E*)-selective hydrostannylation (Bu₃SnH, Pd(PPh₃)₂Cl₂, THF), followed by tin-iodine exchange with iodine (I₂, CH₂Cl₂, 45% yield).¹¹ Deprotection of the C17 hydroxy group proceeded

smoothly to furnish iodide **20** (TBAF, THF) in 72% yield. Thus, the C13–C19 fragment **20** was obtained in 10.6% yield from (*S*)-citronellal (**3**) over 11 steps.

With both major fragments **14** and **20** in hand, the fragment couplings were undertaken. Several avenues were explored, and we present in Scheme 3 the optimum strategy for both yield and RCM (*E*) to (*Z*) selectivity. Coupling of acid **14** with alcohol **20** (DCC, DMAP, CSA, CH₂Cl₂)¹² produced ester **21** in 74% yield. The RCM with Grubbs 1st generation metathesis catalyst gave macrocyclic lactone **22**, as a 1.9:1 (*E/Z*) mixture.¹³ Without separation, **22** was deprotected with DDQ¹⁴ (CH₂Cl₂/H₂O: 20/1, rt). A single flash chromatography purification on silica gel gave (*E*)-macrocyclic **23** in 43% yield (over two steps). The free C8 hydroxy group was converted to the carbamate using a milder base that had been described¹⁵ (Cl₃CONCO, CH₂Cl₂, then NaHCO₃, MeOH) to afford macrocycle **24** in 86% yield. The Stille coupling with the easily prepared stannane **25**, based on conditions reported by Marshall *et al.*¹⁶ [Pd₂(dba)₃•CHCl₃, AsPh₃, LiCl, NMP], proceeded in moderate yield (31%) to provide compound **26**. Finally, the latter was deprotected with TBAF at 0 °C, to minimize basic saponification of the carbamate moiety,¹⁷ and compound **2**¹⁸ was recovered after HPLC purification.¹⁹

Analysis of the α_D , ¹H and ¹³C NMR spectra of **2** showed that it was a stereoisomer of tulearin A. The *J*³ coupling constant between H₂ and H₃ was significantly smaller in the spectrum of the natural product (2.9 Hz) than in isomer **2** (6.9 Hz), so the natural product probably has the 1,2-*anti* configuration. Other resonances in the ¹H NMR spectrum of compound **2** tended to be similar to those of the natural product in both chemical shifts and coupling constants, but because the stereocenters of tulearin are somewhat isolated from each other, further conclusions about stereochemistry are premature.

In summary, a stereoisomer of tulearin A, compound **2**, has been prepared in 0.34% overall yield from (*S*)-citronellal (20 steps for the longest linear sequence) in a total of 32 steps. The synthesis takes into account stereochemical flexibility, so the work paves the way to make other isomers and analogues of tulearin in an expeditious fashion.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Dr. Sablé and Dr. Herman from Sanofi-Aventis (Vitry sur Seine) for purifying compound **2**. DPC thanks l'état et la région Ile-de-France for a Chaire Blaise Pascal and NIH-NIGMS for funding.

References

1. Bishara A, Rudi A, Akin M, Neumann D, Ben-Califa N, Kashman Y. *Org. Lett* 2008;10:153–156. [PubMed: 18085784]
2. Breitenbach R, Chiu CK-F, Massett SS, Meltz M, Murtiashaw CW, Pezzullo SL, Staigers T. *Tetrahedron: Asymmetry* 1996;7:435–422.
3. Blakemore PR, Cole WJ, Kociński PJ, Morley A. *Synlett* 1998:26–28.
4. Sharpless KB, Amberg W, Bennani YL, Crispino GA, Hartung J, Jeong KS, Kwong HL, Morikawa K, Wang ZM. *J. Org. Chem* 1992;57:2768–2771.
5. Sabitha G, Syamala M, Yadav JS. *Org. Lett* 1999;1:1701–1703.
6. Crimmins MT, King BW, Tabet EA, Chaudhary K. *J. Org. Chem* 2001;66:894–902. [PubMed: 11430110]
7. Crimmins MT, Slade DJ. *Org. Lett* 2006;8:2191–2194. [PubMed: 16671814]

8. Matsumura K, Hashiguchi S, Ikariya T, Noyori R. *J. Am. Chem. Soc* 1997;119:8738–8739. Selectivity was confirmed by formation of a MPA-ester and ^1H NMR analysis. See: Seco JM, Quiñoa E, Riguera R. *Chem. Rev* 2004;104:17–118.
9. 1% of catalyst **B** gave **16** in only 10% yield. A high catalyst loading was used, however some starting material could still be recovered from this reaction (39%).
10. Tu YQ, Hübener A, Zhang H, Moore CJ, Fletcher MT, Hayes P, Dettner K, Francke W, McErlean CSP, Kitching W. *Synthesis* 2000:1956–1978.
11. Marshall JA, Bourbeau MP. *J. Org. Chem* 2002;67:2751–2754. [PubMed: 11975524]
12. a) Neises B, Steglich W. *Angew. Chem., Int. Ed. Engl* 1978;17:522–524. b) Boden EP, Keck GE. *J. Org. Chem* 1985;50:2394–2395.
13. Other catalysts such as Grubbs 2nd generation and Hoveyda-Grubbs 2nd generation were unreactive, or when forced, produced byproducts. Understanding that protecting groups can also alter the outcome of methatheses, alternately protected compounds were tried with all of the catalysts but gave poorer selectivities and yields. See: Yamamoto K, Biswas K, Gaul C, Danishefsky SJ. *Tetrahedron Lett* 2003;44:3297–3299. 3299
14. Horita K, Yoshioka T, Tanaka T, Oikawa Y, Yonemitsu O. *Tetrahedron* 1986;42:3021–3028.
15. a) Jiang X, Liu B, Lebreton S, De Brabander JK. *J. Am. Chem. Soc* 2007;129:6386–6387. [PubMed: 17458968] b) Nicolaou KC, Guduru R, Sun Y-P, Banerji B, Chen DY-K. *Angew. Chem., Int. Ed* 2007;46:5896–5900. c) Marshall JA, Johns BA. *J. Org. Chem* 1998;63:7885–7892.
16. Marshall JA, Adams ND. *J. Org. Chem* 2002;67:733–740. [PubMed: 11856013]
17. Under the conditions used for the deprotection step, two byproducts were formed, one appeared to be the macrocyclic lactone wherein the carbamate was cleaved and the other compound corresponds to an allylic rearrangement of the macrocycle producing a 22-membered ring lactone.
18. Compound **2**: $R_f \sim 0.21$ (Hex/EtOAc: 1/4); $[\alpha]_D^{20} = +13$ ($c = 0.04$, CHCl_3); IR: 3361, 2950, 2923, 1707, 1604, 1456, 1394, 1380, 1325, 1250, 1066, 1040, 968, 935 cm^{-1} . ^1H NMR (600 MHz, $(\text{CD}_3)_2\text{CO}$): δ 6.09 (d, $J = 15.5$ Hz, 1H), 5.77 (dt, $J = 15.5$ and 7.0 Hz, 1H), 5.72 (br s, 2H), 5.60 (td, $J = 9.3$ and 5.2, 1H), 5.49 (dt, $J = 15.2$ and 6.5 Hz, 1H), 5.43 (dt, $J = 15.3$ and 6.8 Hz, 1H), 5.23 (d, $J = 9.3$ Hz, 1H), 4.58 (dt, $J = 6.5$ and 5.1 Hz, 1H), 3.81 (m, 1H), 3.67 (m, 1H), 3.61 (d, $J = 6.8$ Hz, 1H), 3.52 (d, $J = 6.2$ Hz, 1H), 2.44 (p_{app} , $J = 6.9$ Hz, 1H), 2.22–1.96 (m, 6H), 1.86 (d, $J = 1.1$ Hz, 3H), 1.72–1.34 (m, 11H) 1.31 (m, 7H), 1.12 (d, $J = 7.0$ Hz, 3H), 0.95 (d, $J = 6.3$ Hz, 3H), 0.92 (d, $J = 6.7$ Hz, 3H), 0.88 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (125 MHz, $(\text{CD}_3)_2\text{CO}$): δ 174.2, 158.0, 138.3, 134.9, 132.6, 131.5, 129.5, 129.0, 77.5, 70.9, 70.7, 70.7, 47.6, 42.5, 41.2, 40.8, 33.9, 33.5, 33.4, 32.2, 30.1, 30.0, 30.0, 29.5, 28.6, 23.2, 20.2, 20.0, 14.3, 13.4, 13.1. HRMS: $[\text{M}+\text{Na}]^+$ calcd. = 558.3765; found: 558.3757.
19. HPLC using a Waters (USA) Xterra MS C₁₈ 7 μm reverse phase column measuring 7.8 mm $\times$ 300 mm with a gradient from 55% MeCN/H₂O to 95% MeCN/H₂O over 25 min.

Figure 1.
Proposed two-dimensional structure of tulearin A

Scheme 1.
 Synthesis of C1–C12 fragment **14**

Scheme 2.
Synthesis of C13–C19 fragment **20**

Scheme 3.
Endgame for the synthesis of **2**